Noxopharm Limited has reported pre-clinical data confirming a survival benefit of adding Veyonda® to 177lutetium-PSMA-617 treatment in prostate cancer.
[Noxopharm Limited (BusinessWire, Inc.)]
6445218 {6445218:G7WRKIWB} apa 50 1 165642 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/ %7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-621bdb1cc6688ac3294e203c8fb27bcd%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22G7WRKIWB%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22parsedDate%22%3A%222021-08-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Ci%3ENoxopharm%20Pre-clinical%20Study%20Confirms%20Survival%20Advantage%20of%20Combination%20LuPSMA%20Therapy%20in%20Prostate%20Cancer%3C%5C%2Fi%3E.%20%282021%2C%20August%2012%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fwww.businesswire.com%5C%2Fnews%5C%2Fhome%5C%2F20210812005153%5C%2Fen%5C%2FNoxopharm-Pre-clinical-Study-Confirms-Survival-Advantage-of-Combination-LuPSMA-Therapy-in-Prostate-Cancer%27%3Ehttps%3A%5C%2F%5C%2Fwww.businesswire.com%5C%2Fnews%5C%2Fhome%5C%2F20210812005153%5C%2Fen%5C%2FNoxopharm-Pre-clinical-Study-Confirms-Survival-Advantage-of-Combination-LuPSMA-Therapy-in-Prostate-Cancer%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DG7WRKIWB%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Noxopharm%20Pre-clinical%20Study%20Confirms%20Survival%20Advantage%20of%20Combination%20LuPSMA%20Therapy%20in%20Prostate%20Cancer%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22Noxopharm%20reports%20pre-clinical%20data%20confirming%20a%20survival%20benefit%20of%20adding%20Veyonda%5Cu00ae%20to%20177lutetium-PSMA-617%20%28LuPSMA%29%20treatment%20in%20prostate%20cancer.%22%2C%22date%22%3A%222021-08-12%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.businesswire.com%5C%2Fnews%5C%2Fhome%5C%2F20210812005153%5C%2Fen%5C%2FNoxopharm-Pre-clinical-Study-Confirms-Survival-Advantage-of-Combination-LuPSMA-Therapy-in-Prostate-Cancer%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-08-12T23%3A14%3A55Z%22%7D%7D%5D%7D 
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News